SCHEMBL365276

SCHEMBL365276

Cn1nccc1-c1ccc(OCc2ccc(C(=O)NS(C)(=O)=O)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 5/20 0.47
MCL1 Q07820 5/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP19A1 P11511 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PORCN Q9H237 1/20 0.47
CD274 Q9NZQ7 1/20 0.46
PTGER4 P35408 1/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
SCN9A Q15858 2/20 0.43
SCN5A Q14524 1/20 0.43
LRRK2 Q5S007 1/20 0.42
KCNH2 Q12809 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diethylamine SCHEMBL16239843 0.95 CYP1A2 (0.46) BCL2L1MCL1CYP1A2CYP3A4CYP2D6
SCHEMBL366221 0.80 HDAC3 (0.49) BCL2L1MCL1SCN9ASCN5AADAM17
SCHEMBL364237 0.79 BCL2L1 (0.72) BCL2L1MCL1ALDH1A1MAPTADAM17
SCHEMBL366512 0.78 PTGER1 (0.51) SCN9ASCN5A
SCHEMBL365645 0.78 ALDH1A1 (0.70) BCL2L1MCL1PTGER4ALDH1A1MAPT
SCHEMBL16239768 0.78 ALDH1A1 (0.70) BCL2L1MCL1PTGER4ALDH1A1MAPT
SCHEMBL364340 0.78 RXRA (0.62) BCL2L1MCL1ALDH1A1MAPTMAPK1
SCHEMBL31530410 0.78 CYP1A2 (0.53) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL365210 0.77 MAOA (0.63) BCL2L1MCL1ALDH1A1MAPTMAPK1
SCHEMBL366812 0.77 MAOB (0.63) BCL2L1MCL1ALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A BCL2L1 3577/4885MCL1 2841/4885CYP1A2 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.